ResMed| (RMD): financials, SEC filings and peers
ResMed| (RMD) is a health care equipment company in the Health Care sector of the S&P 500, headquartered in San Diego, California.
It was founded in 1989 and joined the S&P 500 on July 26, 2017.
Its fiscal year ends in June, and its shares trade on the NYSE.
In its SEC filings it is classified as “Surgical & Medical Instruments & Apparatus”.
ResMed| at a glance
- Revenue (12 months)
- $5.7B
- Revenue growth
- +9.0%
- Operating margin
- 33.0%
- Net income (12 months)
- $1.6B
- Free cash flow (12 months)
- $1.6B
- Cash
- $1.0B
- Debt
- $410M
- Diluted EPS (12 months)
- $10.98
Twelve months to September 30, 2026, from the 10-Q filed October 30, 2026.
Latest twelve months
Over the twelve months to September 30, 2026, ResMed| reported revenue of $5.7 billion, up 9.0% from a year earlier.
Its operating margin was 33.0%: for every $100 of sales, about $33 was left as operating profit.
Net income was $1.6 billion (27.8% of revenue), 10.8% higher than a year earlier.
Operating cash flow was $1.8 billion and capital spending $162 million, leaving free cash flow of $1.6 billion (28.1% of revenue).
At the end of the period it held $1.0 billion in cash and $410 million in debt, a net cash position of $601 million.
The diluted share count fell 2.4% in a year, typically the result of buybacks.
Five-year trend
- Revenue went from $3.2 billion in fiscal 2021 to $5.7 billion in fiscal 2026, about 12.1% a year.
- Revenue has grown for 5 fiscal years in a row.
- Operating margin widened from 28.3% to 33.4% over the same years.
- Free cash flow was positive in each of the last 6 fiscal years.
| Fiscal year | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Revenue | $3.6B | $4.2B | $4.7B | $5.1B | $5.7B |
| Revenue growth | 11.9% | 18.0% | 10.9% | 9.8% | 9.9% |
| Operating margin | 28.0% | 26.8% | 28.2% | 32.7% | 33.4% |
| Net income | $779M | $898M | $1.0B | $1.4B | $1.5B |
| Free cash flow | $216M | $574M | $1.3B | $1.7B | $1.6B |
| Diluted EPS | $5.30 | $6.09 | $6.92 | $9.51 | $10.43 |
Fiscal years as reported in ResMed|’s 10-K filings. Free cash flow is operating cash flow minus capital spending.
Recent SEC filings
- 10-Q filed October 30, 2026 — quarterly report
- 8-K filed October 29, 2026 — Earnings results; Other event
- 8-K filed September 1, 2026 — Other event
- 8-K filed August 17, 2026 — Auditor change; Executive or director change
- 10-K filed August 13, 2026 — annual report
- 8-K filed August 6, 2026 — Earnings results; Other event
- 8-K filed July 7, 2026 — Earnings results; Regulation FD disclosure
- 10-Q filed May 1, 2026 — quarterly report
Companies like ResMed|
Other S&P 500 companies in Health Care Equipment:
- ABTAbbott LaboratoriesNorth Chicago, Illinois
- BAXBaxter InternationalDeerfield, Illinois
- BDXBecton DickinsonFranklin Lakes, New Jersey
- BSXBoston ScientificMarlborough, Massachusetts
- DXCMDexcomSan Diego, California
- EWEdwards LifesciencesIrvine, California
- GEHCGE HealthCareChicago, Illinois
- IDXXIdexx LaboratoriesWestbrook, Maine
More from Health Care
Questions about ResMed|
Is ResMed|'s revenue growing?
Yes. Revenue for the twelve months to September 30, 2026 was $5.7 billion, up 9.0% from a year earlier, according to its SEC filings.
Is ResMed| profitable?
Yes. It earned $1.6 billion in net income over the twelve months to September 30, 2026, a net margin of 27.8%.
Does ResMed| have more cash or more debt?
At September 30, 2026 it had $1.0 billion in cash and $410 million in debt, so more cash than debt.
When did ResMed| last file financial results?
Its latest quarterly report (10-Q) was filed with the SEC on October 30, 2026.
Which companies are similar to ResMed|?
In the S&P 500, ResMed| is grouped in Health Care Equipment within the Health Care sector. Abbott Laboratories (ABT), Baxter International (BAX), Becton Dickinson (BDX), Boston Scientific (BSX), Dexcom (DXCM) are in the same group.
Understand the numbers
Source: ResMed|’s filings with the U.S. Securities and Exchange Commission (EDGAR), retrieved November 11, 2026. Figures are as reported by the company and may be restated. This page is for information only and is not financial advice.